Literature DB >> 19036818

Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.

Nolwenn Jouvenet1, Stuart J D Neil, Maria Zhadina, Trinity Zang, Zerina Kratovac, Youngnam Lee, Matthew McNatt, Theodora Hatziioannou, Paul D Bieniasz.   

Abstract

The expression of many putative antiviral genes is upregulated when cells encounter type I interferon (IFN), but the actual mechanisms by which many IFN-induced gene products inhibit virus replication are poorly understood. A recently identified IFN-induced antiretroviral protein, termed tetherin (previously known as BST-2 or CD317), blocks the release of nascent human immunodeficiency virus type 1 (HIV-1) particles from infected cells, and an HIV-1 accessory protein, Vpu, acts as a viral antagonist of tetherin. Here, we show that tetherin is capable of blocking not only the release of HIV-1 particles but also the release of particles assembled using the major structural proteins of a variety of prototype retroviruses, including members of the alpharetrovirus, betaretrovirus, deltaretrovirus, lentivirus, and spumaretrovirus families. Moreover, we show that the release of particles assembled using filovirus matrix proteins from Marburg virus and Ebola virus is also sensitive to inhibition by tetherin. These findings indicate that tetherin is a broadly specific inhibitor of enveloped particle release, and therefore, inhibition is unlikely to require specific interactions with viral proteins. Nonetheless, tetherin colocalized with nascent virus-like particles generated by several retroviral and filoviral structural proteins, indicating that it is present at, or recruited to, sites of particle assembly. Overall, tetherin is potentially active against many enveloped viruses and likely to be an important component of the antiviral innate immune defense.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036818      PMCID: PMC2643743          DOI: 10.1128/JVI.02211-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Stable gene transfer to the nervous system using a non-primate lentiviral vector.

Authors:  K Mitrophanous; S Yoon; J Rohll; D Patil; F Wilkes; V Kim; S Kingsman; A Kingsman; N Mazarakis
Journal:  Gene Ther       Date:  1999-11       Impact factor: 5.250

2.  HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.

Authors:  J Martin-Serrano; T Zang; P D Bieniasz
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 3.  The replication strategy of foamy viruses.

Authors:  A Rethwilm
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

4.  Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly.

Authors:  S W Eastman; M L Linial
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Vesicular release of ebola virus matrix protein VP40.

Authors:  J Timmins; S Scianimanico; G Schoehn; W Weissenhorn
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

6.  Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors.

Authors:  D Derse; S A Hill; P A Lloyd; B A Morse
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 7.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

8.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

9.  Hypermutation of an ancient human retrovirus by APOBEC3G.

Authors:  Young Nam Lee; Michael H Malim; Paul D Bieniasz
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.

Authors:  Sina Bavari; Catharine M Bosio; Elizabeth Wiegand; Gordon Ruthel; Amy B Will; Thomas W Geisbert; Michael Hevey; Connie Schmaljohn; Alan Schmaljohn; M Javad Aman
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  255 in total

1.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes.

Authors:  Li Ye; Xu Wang; Jieliang Li; Jinping Liu; Servio H Ramirez; Jianguo Wu; Wenzhe Ho
Journal:  Innate Immun       Date:  2011-09-22       Impact factor: 2.680

3.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

4.  BST-2 diminishes HIV-1 infectivity.

Authors:  Jianyong Zhang; Chen Liang
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  Basic residues in the foamy virus Gag protein.

Authors:  Daniel Matthes; Tatiana Wiktorowicz; Juliane Zahn; Jochen Bodem; Nicole Stanke; Dirk Lindemann; Axel Rethwilm
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells.

Authors:  Jason J Rodriguez; Stephen P Goff
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

7.  Regulation of porcine endogenous retrovirus release by porcine and human tetherins.

Authors:  Giada Mattiuzzo; Sabrina Ivol; Yasuhiro Takeuchi
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

9.  Stimulation of NF-κB activity by the HIV restriction factor BST2.

Authors:  Andrey Tokarev; Marissa Suarez; Wilson Kwan; Kathleen Fitzpatrick; Rajendra Singh; John Guatelli
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus.

Authors:  Mandana Mansouri; Kasinath Viswanathan; Janet L Douglas; Jennie Hines; Jean Gustin; Ashlee V Moses; Klaus Früh
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.